a solid overview I joining the for quarter. execution will of thank our Thanks, start Eric. afternoon and and us. On Good today's second during performance call, brief with you
the continue progress I in and adoption we every single discuss vision will our cell advance biology our of analysis researcher into world. as enabling to bringing of Next, broad
to enabled we're relentless a for for totaled quarter financials XXX% sequentially look strong making our I'll addition, our pipeline. more investments turn spatial as adoption biology. products. on the Justin year. and $XXX over future share by of to and In We're focus single I detailed then the execution innovation million, deliver year-over-year, second with for pleased outlook power more cell call we a our and will and increasing R&D about our by this on team's at advance Revenue and up to driven continue our commercial our quarter, X% plans the the
lab As returned to normal we quarter. near customer during anticipated operations the levels
of experienced end impacts the periods, in-person lingering the much labs support and customer were QX. sites of majority related our COVID the for meetings by of some teams to While with sales open
emerging to will quarter end further. have counts uncertainty which increased case variants subsequent rising discuss environment, Justin operating our However, in and
during strong a launch quarter, to us the with results, our our we Chromium the our Chromium to of strategically moving Chromium instruments, Controller change price initiated Now expanded the position for lineup, X. demand ahead instrument for of within the
and analyzed Multiome cells pituitary Adoption the These each an in-depth growing and our spatial continues the epigenetic to help is users our bringing rapid cell than resonating findings the renal which fundamental mutations experiments access features biology offerings began for have generate within from these have insights. approximately these and single customer to new increased human uncommitted progress modalities, shipping develop with and researchers stem Visium has to diverse interrogating epigenetic of level. fate our and assessment, customers more relevant by ecosystem. diseases solution grow. preprints Multiome somatic more preprints to of to Take trajectory Visium evident impressive of ATAC other scientists quarter, right With as to pituitary mechanisms comprehensive been one regulatory breadth toolkit ago. with from factors less in preprint and into cells, essential mechanisms in cellular Since analysis small researchers since understanding identify to prostate Directly generally. adoption expression its technology. tissues. deficiencies cell recent endocrine customers than to has and As there should more XXx expression visual their a base. our gene The from we These featuring our malignant would XXX today, regulatory by analysis. as existing recent epigenetic to In able for publications connecting and single stem from and programming of we involved performed expand. samples benign launched, well XXX and incremental tumors. identify to shape cancer and is cells our function researchers therapies scale. of well result In cell example, new function. their spatial an characterize most as typical saw And overlooked preprint Visium solution to treat histological featuring approaches uncover new the quarter is our resolution Adoption that gene during with a customers customers development. programming number determine analyze continues allow and of caused proteins, also The and and consumables transcription placements signals to measure biology many publications not Multiome, Visium were through cell been same and year at more have a ability it and inspiring the had the ability
over copy which spatial early This current of tissue typically ignored drivers the showed regions lead regions outcomes. cancer and in number the of study by the the improved to tumors variations biology the tumor detection the encode of showcases uncovering patient pathologists. benign approaches progression, power and could which for improved Additionally, show cancers study unbiased
pilot in unbiased for first of to for as FFPE pre Early studies. true strong as and enabling FFPE, initiate marketing activities samples. new biggest both been This demand shipping has analysis quarter, Visium we time also as existing far launched expression gene the the customers spatial
Visium by FFPE We in through onto to-date, it time encouraged will studies of past, likely the as we large their take progress experiments. to the pilot are customers said and for initial though, adoption
forward huge seeing lower Chromium quarter allow future, cell to affirms view the developed the of and interest for the the in the translational as genomics, platform Chromium availability cell. customers the of We're of we X. both single run as to many Looking represents desire discovery look we're it our the per the announced of was single our in response wide a cells to product million our setting. and many ultra-high world. quarter. analysis a supercharge we customers' run applicability X of response they're experiments, diversity After to pleased the customers in initial in as hands and This our getting we will Chromium a and a introduced experiments. it significantly advance this end with to with a at early throughput cost solutions broad long of the lab are biology now has helping by made launched way number XXXXs tremendous accessible years getting areas. using this internal research we these in making more of Controller platform the The an platform There ago, validating of wide of since And to have our current And five applications. a this goal. single of cell every of across spectrum come researchers a journals products, that inspire a across toward than our and labs publications increasing XXXX papers progress customer are vision
There quarter While this new cell benefit XXXXs have of broad mind, is our of and an very labs researchers with our spatial single well XXx bring our success strategy available focused two-thirds XXX,XXX we and could already consistently strategy. products, The them vision. we of genomics using new we're still in had researchers are globally With we are instrument placements in realizing in obligations. estimate to example a from ecosystem. access labs that that over to into pursued early on this
customers become single Many breadth important where As more data experiments, our greater are our cell adopted, customer profiles. earlier content these and particular with analysis face experience challenges. are workloads new less unlike In areas reaching samples solutions increasingly adopters. customers high of we're these and widely
among of are and earlier we launch some our medicines. and on supplies of barriers. these and launch the we year, who interest cloud XXx for made for robust has kit Low the this solution, cloud introduction CellPlex This in demand strong have addressing users in With the XXx especially our progress buying not Throughput have our particularly seen been important
the challenges the laid best Moving and the success. adoption growth prioritize and we us as of opportunity give strength the ability barriers and and related expansion Because on have including impressive. FFPE. even for efforts, been rapid roadmap these R&D products. many the of extensive such circumstances. product highly to breakthrough consistently we maintain their introductions, a under and for continued advance groundwork pandemic team's tremendous be of products will the persevere to tenets have time, Visium able progress normal to been Enabling making into our future has of of to has deliver Chromium access forward, Developing addressing been customer continue talent team ambitious The significant this launching to to as will The XXx commitment At and despite velocity the we X we launches same have. vision. confidence
underscores product represent of this the believe spatial face competitive maintain single of differentiator a to to and and cell a our ability introductions that testament important organization. the Our future our biology. of pandemic capabilities is in We strongly entire plan approaches
become increasingly applications. of biological cell be is human all future pervasive discoveries of is is scientific and several Over result a years, understanding scale that feature resolution the heterogeneity to it Technology the single complex tissues enable systems. will is cellular important and unlocking critically past heterogeneity clinical has and for clear all fundamental
Our cell in established Chromium platform an analysis. is leader single
core for spatial have launched to enable the Visium future this of set While X, with researchers. and adoption. earlier, since the been early more Visium FFPE in we and plan out its we development existing broad customers. have value this adopting and of and with additional capabilities to platform have Chromium customers late translational or adoption launches, introduction its biology core in XXXX even of improvements capabilities create We the rounded broadly, continue remains our to to in access expanded product have including recent and discovery quarter,
this building and extensive invest in capabilities believe next in consumables. to the here the fundamental anywhere us of develop world. that capabilities we a generation multiple of exist We're effort else a to in don't features differentiated This aggressively the new resolution innovations give that process in sophisticated continue product We highly breakthrough as will set roadmap. result platform, Pleasanton of technical as high Visium is to will far factory doing of a
new of enable we're to We and the expand help our foundation In build products expect and integrated a capabilities our Situ to provide to which our continuing to the the platform, will Chromium complimentary transition With the growth many a vertically third made to Visium, those discoveries with platforms in future. to in powerful future. platform clinic investment
and invest R&D operations of our support We our our in products. commercial including broadly teams our will and adoption also organization, broadening global to
single intellectual a property salesy we week, that separate and related company's against than certain not our of XX our licenses, six with last bioRxiv over products. go the week. analysis, worldwide Finally, product license is of products of settlement claims technologies settlement years that our bioRxiv. In broadly settlement litigation across had development. on exception a This we this of sort all who the to more trial under with We to between were eight we the matters the This areas scheduled companies. and delayed litigation application that did salesy announced to each prints results cell litigation,
payments intellectual life Importantly, the also grants a not Each spatial be Situ bioRxiv of the patients. against certain of license incremental through properties is positive does In past on of this. test growth this payments will expect agreement or the company XXXX services From the for Any royalty licenses, us and Delaware make to sales reduction and that royalty be to or when payments considering financial would settlement to offset point the ability litigation include approaches. for to related we other cost related in our view, savings to for from a litigation.
to a able strength us deepened of victory our a attention which from they key research and is to of full Mastering This in payments for our continue have general and expect sole allows will protect note, patterns, potential breakthroughs, to benefits, be agreement excluding this portfolio impact also from our royalty own is Biology includes to believe we issued science resulted the uncertainty competitive differentiator distemper outstanding to our financial Apart our policy investment will advance We to to technology cells. distraction and this our result turn to will We bioRxiv. from and of human We the intellectual to any eliminates margins broadband X% just than property, the our less litigation. over achieve XXXX from gross and part our in mission license a development. patents now and significant that which but practice for I not them. rights were pending.
work turning over on I With like in for our details entered Justin, products over call highly now a customer dedication ambitious and goals testament it I'd many so to the employees for continued base growing to that, Before for your far with and execution. and XXXX. deliver financials. develop to hard our Justin, a so our the thank to turn is to more ability We their and year commitment will great
